Medical Technologies Innovation and Knowledge Centre Phase 2 Regenerative Devices

再生装置（支架、生物材料和干预）可以使用患者自己的细胞修复和再生组织，可以转化为成功的临床产品，并以更低的成本和风险为患者带来益处，并且在更短的时间内比其他再生疗法（如培养扩展细胞疗法或分子（药物）疗法）更短。据估计，到2020年，全球再生设备市场将增长到500亿英镑，这为英国在这一领域每年增长10亿英镑的行业提供了真正的机会。英国在生物材料和组织工程、肌肉骨骼力学（EPSRC优先考虑）和再生医学领域拥有真正的研究优势。再生医学是研究委员会优先考虑的八大技术之一。研究发现、新知识、产出和成果往往还没有准备好被行业吸收，无法通过产品开发推向市场并使患者受益。需要发展新技术，降低风险。临床需求、潜在产品和市场需要明确，以使其对投资、产品开发和行业临床试验具有吸引力。在医疗技术创新和知识中心（MTIKC）的第一阶段，我们与行业和临床合作伙伴合作，建立了一支专业的创新团队和独特的创新和转化流程，创建了一个多学科的研究和创新生态系统。我们已经成功地确定了研究成果和新知识，并创造了跨越死亡创新谷的先进和转化技术，使工业和私营部门在新产品开发方面成功投资（超过1亿英镑）。一些产品已经进入临床试验和商业化阶段，并正在为患者带来益处。我们已经建立了一个持续的创新管道，超过50个概念技术项目的验证。在未来五年的MTIKC二期，我们将在伤口修复、心血管修复、肌肉骨骼组织修复、颌面重建、牙齿重建和普通外科等领域解决尚未满足的临床需求和市场机会，并将我们的研究供应链多元化到其他十多所大学。我们将支持150个与工业界的合作项目，并启动40个新的工业启发和学术主导的概念验证项目，预计这些项目将导致私营部门在后续产品开发中进一步投资1亿英镑。这将使英国建立一个可持续的研究和产品开发管道，这将支持2020年以后再生设备行业每年10亿英镑的发展。

Regenerative devices (scaffolds, biomaterials and interventions) which can repair and regenerate tissues using the patients` own cells, can be translated into successful clinical products and deliver patient benefit at much lower cost and risk and in shorter timescales then other regenerative therapies such as culture expanded cell therapies or molecular (drug) therapies. It is estimated that the global market for regenerative devices will grow to £50bn by 2020 and this offers a real opportunity to grow a £1bn per year industry in the UK in this field. The UK has genuine research strengths in the areas of biomaterials and tissue engineering, musculoskeletal mechanics (prioritised by EPSRC) and regenerative medicine. Regenerative medicine is one of the eight great technologies prioritised across the Research Councils. Research discoveries, new knowledge, outputs and outcomes are often not ready for uptake by industry to take forward through product development to the market and patient benefit. New technologies need to be advanced and de-risked. The clinical needs, potential products and markets need to be defined in order to make them attractive for investment, product development and clinical trials by industry. In the Medical Technologies Innovation and Knowledge Centre (MTIKC) Phase 1, working with industry and clinical partners, we have developed a professional innovation team and a unique innovation and translation process, creating a multidisciplinary research and innovation ecosystem. We have successfully identified research outcomes and new knowledge and created, advanced and translated technology across the innovation valley of death, enabling successful investment (over £100m) by industry and the private sector in new product development. Some products have already progressed to clinical trials and commercialisation and are realising patient benefits. We have established a continuous innovation pipeline of over fifty proofs of concept technology projects.Over the next five years in MTIKC Phase 2, we will address unmet clinical needs and market opportunities in wound repair, cardiovascular repair, musculoskeletal tissue repair, maxillofacial reconstruction, dental reconstruction and general surgery and diversify our research supply chain to over ten other Universities. We will support 150 collaborative projects with industry and initiate forty new industry inspired and academically led proof of concept projects, which are predicted to lead to a further £100m investment by the private sector in subsequent product development. This will enable a sustainable research and product development pipeline to be established in the UK which will support a £1bn / year industry in regenerative devices beyond 2020.